Optimizing next-generation AML therapy: Activity of mutant IDH2 inhibitor AG-221 in preclinical models

Daniel Thomas, Ravindra Majeti

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

AG-221 or enasidenib is a first-in-class selective inhibitor of mutated isocitrate dehydrogenase 2 (IDH2) with early demonstrated clinical efficacy in acute myeloid leukemia as a single agent, yet with persistence of mutant IDH2 clones. Two articles in this issue of Cancer Discovery provide further insight into the biological activity of AG-221 in promoting differentiation of IDH2-mutant cells and reversing aberrant DNA methylation over time, and demonstrating preclinical activity in combination with a targeted FLT3 kinase inhibitor to eliminate IDH2-mutant clones.

Original languageEnglish
Pages (from-to)459-461
Number of pages3
JournalCancer Discovery
Volume7
Issue number5
DOIs
Publication statusPublished - May 2017
Externally publishedYes

ASJC Scopus subject areas

  • Oncology

Cite this